CN110947028A - 一种黄豆浸取液制备的Ag纳米粒子及其液体创口贴制备方法 - Google Patents
一种黄豆浸取液制备的Ag纳米粒子及其液体创口贴制备方法 Download PDFInfo
- Publication number
- CN110947028A CN110947028A CN201911238317.8A CN201911238317A CN110947028A CN 110947028 A CN110947028 A CN 110947028A CN 201911238317 A CN201911238317 A CN 201911238317A CN 110947028 A CN110947028 A CN 110947028A
- Authority
- CN
- China
- Prior art keywords
- solution
- ethanol
- silver
- mul
- soybean
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 43
- 244000068988 Glycine max Species 0.000 title claims abstract description 40
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 40
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 31
- 239000000853 adhesive Substances 0.000 title claims abstract description 28
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000002386 leaching Methods 0.000 title claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 127
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000008367 deionised water Substances 0.000 claims abstract description 23
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 23
- 239000004332 silver Substances 0.000 claims abstract description 17
- 229910052709 silver Inorganic materials 0.000 claims abstract description 17
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000005406 washing Methods 0.000 claims abstract description 16
- 238000002791 soaking Methods 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000002244 precipitate Substances 0.000 claims abstract description 10
- 238000004140 cleaning Methods 0.000 claims abstract description 8
- 229910001961 silver nitrate Inorganic materials 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 6
- 150000002333 glycines Chemical class 0.000 claims abstract description 3
- 210000000582 semen Anatomy 0.000 claims abstract description 3
- 238000000926 separation method Methods 0.000 claims abstract description 3
- 235000019441 ethanol Nutrition 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 35
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 16
- 239000011505 plaster Substances 0.000 claims description 14
- 239000000020 Nitrocellulose Substances 0.000 claims description 12
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims description 12
- 229920001220 nitrocellulos Polymers 0.000 claims description 12
- 235000020712 soy bean extract Nutrition 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 239000011259 mixed solution Substances 0.000 claims description 9
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 8
- 235000021314 Palmitic acid Nutrition 0.000 claims description 8
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 8
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 8
- 239000008399 tap water Substances 0.000 claims description 8
- 235000020679 tap water Nutrition 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 229960001295 tocopherol Drugs 0.000 claims description 7
- 229930003799 tocopherol Natural products 0.000 claims description 7
- 235000010384 tocopherol Nutrition 0.000 claims description 7
- 239000011732 tocopherol Substances 0.000 claims description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- DSSYKIVIOFKYAU-UHFFFAOYSA-N camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 4
- 239000000428 dust Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 26
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 3
- 206010052428 Wound Diseases 0.000 description 36
- 208000027418 Wounds and injury Diseases 0.000 description 36
- 241000894006 Bacteria Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 239000002904 solvent Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 4
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 4
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 4
- 235000008696 isoflavones Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000002390 adhesive tape Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- -1 silver ions Chemical class 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000404844 Callicarpa nudiflora Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 240000004824 Trimezia steyermarkii Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000009136 dragon's blood Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
- B22F9/16—Making metallic powder or suspensions thereof using chemical processes
- B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
- B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明涉及医药领域,即一种黄豆浸取液制备的Ag纳米粒子及其液体创口贴制备方法。其特征在于步骤如下:(1)选料。(2)清洗。(3)浸泡。(4)制备银纳米粒子:在所获得的黄豆浸取液中加入3升浓度为0.01‑0.05 mol·L‑1的硝酸银水溶液在室温下继续静置24小时后,获得黄色或橙色溶液。(5)分离清洗:将步骤(4)获得的溶液于1000rpm的条件下离心10分钟,所获得的沉淀用去离子水清洗两次,乙醇清洗一次,然后分散到1.4升的无水乙醇中,得尺寸为5‑20 nm的银纳米粒子乙醇悬浊液,待用。该制备方法绿色、环保、低耗、生物相容性良好,且所制备的银纳米粒子具有良好的广谱抗菌性能。
Description
技术领域
本发明涉及医药领域,即一种黄豆浸取液制备的Ag纳米粒子及其液体创口贴制备方法。
背景技术
在现有技术中,有人类社会以来,细菌就一直伴随在人类左右。20世纪初期,医学研究已经认识到很多疾病都是因为细菌感染而引起的,但却不知道如何消灭细菌。后来通过大量的研究,科学家发现有一些微生物会对另外一些微生物的生长繁殖有一定的抑制作用,由此为契机,人们发现了抗生素,其中就包括著名的青霉素。抗生素的使用挽救了成千上万人的生命,特别是在第二次世界大战期间,以前被认为必死无疑的结核、肺炎、败血症都得到了治愈。随着更多种抗生素的发现以及愈来愈多的治愈病例,人们对抗生素产生了崇拜,甚至是预言,“就在这一代人的时间里,医学即将战胜并掌控所有人类的外部敌人”。但是,慢慢地,人们发现,同样剂量的抗生素治疗效果却变差了,这是细菌耐药的结果。于是人们又研制出了更高级别的抗生素,如替加环素、万古霉素,但很快这些抗生素也被细菌耐受了,这样的细菌在医学上被称之为“全耐药细菌”或“多重耐药性细菌”,也就是我们口中常称的“超级细菌”。“超级细菌”对几乎所有的抗生素都具备很强的抵御能力。如鲍曼不动杆菌就是一种“超级细菌”,如果感染上了这种细菌,70%的人存活率不会超过一个月。因此,寻找能够对抗超级细菌的有效药物成为一个研究热点。纳米粒子因其独特的抗菌性能开创了与病菌对抗的新路径,并且表现出良好的应用前景。这是因为纳米材料的抗菌是物理抗菌,不同于传统的抗生素作用机理,因此细菌不会产生耐药性,是对抗“超级细菌”的最佳手段之一。
银纳米材料在诸如抗糖尿病、抗疟原虫、抗肿瘤、抗炎症和抗真菌感染等医药领域已有广泛的应用,而近年来的研究表明,纳米尺度的银的抗菌性能优异,无论是革兰氏阳性还是革兰氏阴性的细菌以及真菌都具有良好的抗菌性能。目前广为接受的纳米银抗菌机理为:(1)纳米银可以损伤细菌的DNA,使得细菌的遗传物质无法正常复制,从而失去繁殖能力。(2)纳米银释放的银离子能够激活空气或水中的氧,产生具有强氧化性的羟基自由基和活性氧物种,可以杀灭细菌。(3)纳米银释放的Ag离子能与细菌蛋白酶上的巯基(—SH)结合,使蛋白酶丧失活性,导致细菌死亡。细菌死亡后,银离子又从细菌体中游离出来,再与其它细菌接触,并周而复始地进行上述过程,从而使纳米银获得持久性的抗菌作用。由于纳米银的广谱以及持久抗菌特性,科学家们已经研制出了纳米银纱布,不仅能促进伤口愈合、防治感染,还能减轻术后伤口疼痛,目前已经广泛应用于临床治疗。
创口贴已经成为医院、诊所、家庭中最常用的急救必备医疗用品,用于小创口、擦伤、切割伤等浅表性创面的急救及临时性包扎。传统的绷带创口贴都是固体材料制成的长胶布,通常由涂胶基材、吸收性敷垫、防粘连层和可剥离的保护层组成,但这类创口贴所用的胶布透气性差,人体局部所正常分泌的水汽和汗液不能穿透这层胶布,于是对局部皮肤产生浸泡作用,患者的使用舒适度大大下降,特别是患处在手部而又不得不进行沾水性工作的时候,创口贴的里外都浸满了水,反而不利于伤口的愈合。尽管后来出现了所谓的“防水型创口贴”,但实际体验表明并不能做到完全防水。而且为了使创口贴固定在创口表面,起固定作用的胶基部分面积较大,患处位于暴露处时会影响美观,即便现在有各种卡通或印花创口贴出售。于是人们发明了液体创口贴,该类创口贴为透明液体或膏体,由能够成膜的有机高分子及其溶剂组成。在使用时,取适量液体创口贴涂布在伤口表面,随着溶剂的挥发,在伤口表面形成薄薄一层透明的薄膜。与传统的绷带创口贴相比,液体创口贴更轻薄,涂抹的部位也不会出现因为胶布过紧不透气而发白不过血等问题,膜体紧紧贴着伤口,不会进水,正常洗脸洗手洗澡都没关系。因此,液体创口贴一经面世便受到广泛欢迎。
在成膜的基础上,很多抗菌消炎物质被加入液体创口贴中以提高其功效性,例如蜂胶、裸花紫珠、三七和龙血竭等中药的提取液和以银为主的纳米材料。为了控制材料的尺度在纳米范围,纳米银的制备通常需要引入表面活性剂等封端分子,但这类分子大部分具有一定的生物毒性,不适合用于医药健康领域。因此,液体创口贴中使用的纳米银应当是绿色制备且生物相容性良好。另外,纳米银的尺寸必须适度,过大的银纳米粒子将会影响成膜的效果以及膜的韧性。
本发明公开了一种以黄豆浸取液制备生物相容性良好的银纳米粒子的方法及以之为抗菌材料的液体创口贴的制备方法。该发明所涉及的纳米粒子制备方法绿色环保、成本低廉、尺寸合理,实验表明所得纳米银具有良好的抗菌性能并尺寸较小(5-20 nm),能够很好的分散在液体创口贴中而不影响成膜效果。
发明内容
本发明的目的是提供一种黄豆浸取液制备的Ag纳米粒子及其液体创口贴制备方法;提供具有良好的生物相容性和抗菌活性的银纳米粒子;提供具有广谱的抗菌活性,且抗菌活性高、时效长的液体创口贴。
一种黄豆浸取液制备Ag纳米粒子的制备方法,其特征在于步骤如下:
(1)选料:普通市售黄豆。
(2)清洗:先用自来水洗去表面灰尘和杂质,然后用去离子水清洗两遍以去除黄豆表面附着的自来水中的离子,最后用无水乙醇或95%乙醇清洗一次以去除黄豆表面附着的油脂。
(3)浸泡:将黄豆浸泡到去离子水中以浸出黄豆中的水溶性还原物质,1千克黄豆用水量为7-21升,在室温下浸泡24小时后分离泡胀的黄豆它用(可以用于制做豆制品),得黄豆浸取液。
(4)制备银纳米粒子:在所获得的黄豆浸取液中加入3升浓度为0.01-0.05 mol·L-1的硝酸银水溶液(硝酸银水溶液与黄豆浸取液的比例为1:0.4~0.1)在室温下继续静置24小时后,获得黄色或橙色溶液(见附图1)。
(5)分离清洗:将步骤(4)获得的溶液于1000rpm的条件下离心10分钟,所获得的沉淀用去离子水清洗两次,乙醇清洗一次,然后分散到1.4升的无水乙醇中,得尺寸为5-20 nm的银纳米粒子乙醇悬浊液(透射电子显微镜图片示于附图2),待用。
优选,黄豆浸取液制备Ag纳米粒子的制备方法,其特征在于步骤如下:取黄豆1千克先后用自来水、去离子水和乙醇依次清洗干净,然后浸入7升去离子水,在室温下浸泡24小时后弃去泡胀的黄豆;在所获得的黄豆浸取液中加入3升浓度为0.01mol·L-1的硝酸银水溶液,在室温下继续静置24小时后,获得黄色溶液;将此溶液于1000rpm的条件下离心10分钟,所获得的沉淀用去离子水清洗两次,乙醇清洗一次,获得尺寸5-10 nm的银纳米粒子,然后分散到1.4升的乙醇中,得银纳米粒子乙醇悬浊液,待用。
含有黄豆浸取液制备的Ag纳米粒子的液体创口贴制备方法,其特征在于步骤如下:
取含质量百分比4-5%的硝酸纤维素的乙醇和乙醚混合溶液(乙醇和乙醚的体积比为6:18)80-90份,蓖麻油0.15-0.2份,生育酚乙酸乙酯0.15-0.2份,乙酸乙酯0.15-0.2份,乙酸丁酯0.15-0.2份,苯甲醇0.15-0.2份,异丙醇0.15-0.2份,混合成无色透明带有粘度的溶液,然后加入棕榈酸(1.7-2 g/L)和混旋樟脑磺酸(0.8-1 g/L),待完全溶解后加入0.3-0.9份的银纳米粒子乙醇悬浊液即获得成膜性良好的液体创口贴。其中,硝酸纤维素起成膜作用,乙醇和乙醚混合溶液是硝酸纤维素的溶剂,硝酸纤维素的乙醇和乙醚混合溶液涂在物体表面上,溶剂因为低沸点而迅速蒸发,留下一层不渗水的坚韧薄膜。蓖麻油与硝酸纤维素具有良好的相溶性,起增塑剂作用,增加膜的塑性。生育酚乙酸酯是一种广泛用于各种个人护理和卫生用品的物质,既是皮肤调节剂,也是抗氧化剂,对皮肤起保护作用。乙酸乙酯、乙酸丁酯、苯甲醇是硝酸纤维素的快干溶剂,且都具有芳香气味,使液体创口贴气味宜人。异丙醇是硝酸纤维素的良溶剂,本方法中起到助溶的作用。棕榈酸起防水作用。混旋樟脑磺酸具有改善血液循环、促进新陈代谢机能的作用。银纳米粒子是抗菌成分。以上所有试剂组合成为具有抗菌功能的、气味宜人的、略有一定粘度的透明或半透明液体,随着银纳米粒子用量的增加,液体创口贴的透明度略有降低(见附图3)。
优选,一种含有黄豆浸取液制备的Ag纳米粒子的液体创口贴制备方法,其特征在于步骤如下:取含质量百分比4-5%的硝酸纤维素的乙醇和乙醚混合溶液15 mL,蓖麻油250μL,生育酚乙酸乙酯250 μL,乙酸乙酯250 μL,乙酸丁酯250 μL,苯甲醇250 μL,异丙醇250μL,混合成无色透明带有粘度的溶液,然后加入棕榈酸0.025 g和混旋樟脑磺酸0.0125 g,待完全溶解后加入1000 μL的银纳米粒子乙醇悬浊液即获得成膜性良好的液体创口贴(见附图4、图5)。
在去离子水的浸泡下黄豆中有10%的异黄酮外渗到水溶液中,大豆异黄酮是一种多酚类混合物,是黄豆中最有医疗价值的活性成分,由于其结构中存在酚羟基,易被氧化,故具有抗氧化作用,是一种良好的天然抗氧化剂和还原剂。黄豆浸出物中的这些还原物质可将银离子还原为银单质,而且在浸出物的保护和限制下不会生长为大尺寸粒子。根据浸泡黄豆的水量不同,银纳米粒子的尺寸可在5 nm至20 nm之间调整(银纳米粒子的尺寸和含量对液体创口贴的成膜效果影响很大,银纳米粒子超过100 nm,用量超过1.5份时对液体创口贴的成膜效果不好,具体表现为需要反复涂抹才能在皮肤上成膜,而且成膜厚度薄、易碎、不能成片剥离)。由于制备所采用的原材料是可食用物质,因此所获得的银纳米粒子具有良好的生物相容性。针对革兰氏阳性菌大肠杆菌和革兰氏阴性菌金黄色葡萄球菌的抗菌实验表明所制备的银纳米粒子具有良好的广谱抗菌性能(见附图6、7)。在附图6、7中,在载有银纳米粒子的滤纸片周围可以看到明显的抑菌圈,说明其良好的抗菌性能。
本发明提供的含有银纳米粒子的液体创口贴具有广谱的抗菌活性,且抗菌活性高、时效长。
液体创口贴使用方法:
方法一、将液体创口贴装入玻璃或塑料瓶中,盖子自带小软刷,使用时用软刷蘸取适量液体涂敷于创口表面,自然晾干1-2分钟,即可在创口上获得薄膜(见图4)。不需要时可随时揭下薄膜(见图5)。
方法二:将液体创口贴灌装入牙膏管状的软管中,使用时经管口挤出并均匀涂抹于创口皮肤上,自然晾干1-2分钟,即可在创口上获得薄膜。不需要时可随时揭下薄膜。
本发明优点是:
1、本发明以可食用物质黄豆的浸取液作为还原剂和封端剂制备了尺寸为5-20 nm之间的银纳米粒子,该制备方法绿色、环保、低耗、生物相容性良好,且所制备的银纳米粒子具有良好的广谱抗菌性能。
2、本发明改善了传统的创口贴适用性窄、愈合缓慢、透气性差的特性,适用于更多的伤口和更广的使用范围,在创口成膜后具有疏水性,用户可以适度从事接触水的工作,同时加入了具有抗菌活性的银纳米粒子,使得液体创口贴具有长效且良好的抗菌活性,更有利于伤口愈合。
下面将结合实施例对本发明做进一步说明。
附图说明
图1是黄豆浸取液制备的Ag纳米粒子的照片。
图2是Ag纳米粒子的透射电子显微镜图像。
图3是不同银纳米粒子用量时所得液体创口贴的照片。
图4是液体创口贴在皮肤上成膜情况。
图5是液体创口贴在皮肤上成膜一天后剥离的整片膜。
图6是浸取液制备的Ag纳米粒子的抗菌效果图-大肠杆菌。
图7是黄豆浸取液制备的Ag纳米粒子的抗菌效果图-金黄色葡萄球。菌。
具体实施方式
实施例1
1. 取市售普通黄豆1千克先后用自来水、去离子水和乙醇依次清洗干净,然后浸入7升去离子水,在室温下浸泡24小时后弃去泡胀的黄豆。在所获得的黄豆浸取液中加入3升浓度为0.01mol·L-1的硝酸银水溶液,在室温下继续静置24小时后,获得黄色溶液。将此溶液于1000rpm的条件下离心10分钟,所获得的沉淀用去离子水清洗两次,乙醇清洗一次,获得尺寸5-10 nm的银纳米粒子,然后分散到1.4升的乙醇中待用。
2. 取含质量百分比4-5%的硝酸纤维素的乙醇和乙醚混合溶液15 mL,蓖麻油250μL,生育酚乙酸乙酯250 μL,乙酸乙酯250 μL,乙酸丁酯250 μL,苯甲醇250 μL,异丙醇250μL,混合成无色透明带有一定粘度的溶液,然后加入棕榈酸0.025 g和混旋樟脑磺酸0.0125g,待完全溶解后加入1000μL的银纳米粒子乙醇悬浊液即获得成膜性良好的液体创口贴。
实施例2
1. 取市售普通黄豆0.7 g先后用自来水、去离子水和乙醇依次清洗干净,然后浸入5mL去离子水,在室温下浸泡24小时后弃去泡胀的黄豆。在所获得的黄豆浸取液中加入2 mL浓度为0.01mol·L-1的硝酸银水溶液,在室温下继续静置24小时后,获得黄色溶液。将此溶液于1000rpm的条件下离心10分钟,所获得的沉淀用去离子水清洗两次,乙醇清洗一次,获得尺寸5-10 nm的银纳米粒子,然后分散到1 mL的乙醇中待用。
2.取取含质量百分比4-5%的硝酸纤维素的乙醇和乙醚混合溶液3 mL,蓖麻油50 μL,生育酚乙酸乙酯50 μL,乙酸乙酯50 μL,乙酸丁酯50 μL,苯甲醇50 μL,异丙醇50 μL,混合成无色透明带有一定粘度的溶液,然后加入棕榈酸0.005 g和混旋樟脑磺酸0.0025 g,待完全溶解后加入200μL的银纳米粒子乙醇悬浊液即获得成膜性良好的液体创口贴。
实施例3
1. 取市售普通黄豆0.7 g先后用自来水、去离子水和乙醇依次清洗干净,然后浸入10mL去离子水,在室温下浸泡24小时后弃去泡胀的黄豆。在所获得的黄豆浸取液中加入2 mL浓度为0.01mol·L-1的硝酸银水溶液,在室温下继续静置24小时后,获得黄色溶液。将此溶液于1000rpm的条件下离心10分钟,所获得的沉淀用去离子水清洗两次,乙醇清洗一次,获得尺寸10-20 nm的银纳米粒子,然后分散到1 mL的乙醇中待用。
2. 取含质量百分比4-5%的硝酸纤维素的乙醇和乙醚混合溶液6 mL,蓖麻油100 μL,生育酚乙酸乙酯100 μL,乙酸乙酯100 μL,乙酸丁酯100 μL,苯甲醇100 μL,异丙醇100 μL,混合成无色透明带有一定粘度的溶液,然后加入棕榈酸0.01 g和混旋樟脑磺酸0.005 g,待完全溶解后加入400μL的银纳米粒子乙醇悬浊液即获得成膜性良好的液体创口贴。
上面描述,只是本发明的具体实施方式,各种举例说明不对本发明的实质内容构成限制。
Claims (4)
1.一种黄豆浸取液制备Ag纳米粒子的制备方法,其特征在于步骤如下:
(1)选料:黄豆;
(2)清洗:先用自来水洗去表面灰尘和杂质,然后用去离子水清洗两遍,最后用无水乙醇或95%乙醇清洗一次;
(3)浸泡:将黄豆浸泡到去离子水中,1千克黄豆用水量为7-21升,在室温下浸泡24小时后分离泡胀的黄豆它用,得黄豆浸取液;
(4)制备银纳米粒子:在所获得的黄豆浸取液中加入3升浓度为0.01-0.05 mol·L-1的硝酸银水溶液,在室温下继续静置24小时后,获得黄色或橙色溶液,硝酸银水溶液与黄豆浸取液的比例为1:0.4~0.1;
(5)分离清洗:将步骤(4)获得的溶液于1000rpm的条件下离心10分钟,所获得的沉淀用去离子水清洗两次,乙醇清洗一次,然后分散到1.4升的无水乙醇中,得尺寸为5-20 nm的银纳米粒子乙醇悬浊液,待用。
2.如权利要求1所述的黄豆浸取液制备Ag纳米粒子的制备方法,其特征在于步骤如下:取黄豆1千克先后用自来水、去离子水和乙醇依次清洗干净,然后浸入7升去离子水,在室温下浸泡24小时后弃去泡胀的黄豆;在所获得的黄豆浸取液中加入3升浓度为0.01mol·L-1的硝酸银水溶液,在室温下继续静置24小时后,获得黄色溶液;将此溶液于1000rpm的条件下离心10分钟,所获得的沉淀用去离子水清洗两次,乙醇清洗一次,获得尺寸5-10 nm的银纳米粒子,然后分散到1.4升的乙醇中,得银纳米粒子乙醇悬浊液,待用。
3.一种含有黄豆浸取液制备的Ag纳米粒子的液体创口贴制备方法,其特征在于步骤如下:
取含质量百分比4-5%的硝酸纤维素的乙醇和乙醚混合溶液80-90份,蓖麻油0.15-0.2份,生育酚乙酸乙酯0.15-0.2份,乙酸乙酯0.15-0.2份,乙酸丁酯0.15-0.2份,苯甲醇0.15-0.2份,异丙醇0.15-0.2份,混合成无色透明带有粘度的溶液,然后加入棕榈酸(1.7-2 g/L)和混旋樟脑磺酸(0.8-1 g/L),待完全溶解后加入0.3-0.9份的银纳米粒子乙醇悬浊液即获得成膜性良好的液体创口贴。
4.如权利要求3所述的一种含有黄豆浸取液制备的Ag纳米粒子的液体创口贴制备方法,其特征在于步骤如下:取取含质量百分比4-5%的硝酸纤维素的乙醇和乙醚混合溶液15mL,蓖麻油250 μL,生育酚乙酸乙酯250 μL,乙酸乙酯250 μL,乙酸丁酯250 μL,苯甲醇250μL,异丙醇250 μL,混合成无色透明带有粘度的溶液,然后加入棕榈酸0.025 g和混旋樟脑磺酸0.0125 g,待完全溶解后加入1000μL的银纳米粒子乙醇悬浊液即获得成膜性良好的液体创口贴。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911238317.8A CN110947028A (zh) | 2019-12-06 | 2019-12-06 | 一种黄豆浸取液制备的Ag纳米粒子及其液体创口贴制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911238317.8A CN110947028A (zh) | 2019-12-06 | 2019-12-06 | 一种黄豆浸取液制备的Ag纳米粒子及其液体创口贴制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110947028A true CN110947028A (zh) | 2020-04-03 |
Family
ID=69980022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911238317.8A Pending CN110947028A (zh) | 2019-12-06 | 2019-12-06 | 一种黄豆浸取液制备的Ag纳米粒子及其液体创口贴制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110947028A (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102941354A (zh) * | 2012-12-05 | 2013-02-27 | 苏州大学 | 一种均匀稳定的纳米银水溶液的制备方法 |
| CN105664168A (zh) * | 2016-03-02 | 2016-06-15 | 中国科学院武汉植物园 | 一种载药纳米银粒子的制备方法及应用 |
| CN106075557A (zh) * | 2016-06-24 | 2016-11-09 | 青岛中腾生物技术有限公司 | 一种可形成含有纳米孔隙柔性膜的液体创口保护材料 |
| CN106924803A (zh) * | 2017-05-05 | 2017-07-07 | 江南大学 | 一种高性能医用液体创可贴及其制备方法 |
| CN108578762A (zh) * | 2018-05-21 | 2018-09-28 | 上海耐定工贸有限公司 | 一种方便快捷的液体创口贴及其制备方法 |
| CN108904876A (zh) * | 2018-10-15 | 2018-11-30 | 长春艾迪尔医用科技发展有限公司 | 一种液体创口敷料及其制备方法 |
-
2019
- 2019-12-06 CN CN201911238317.8A patent/CN110947028A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102941354A (zh) * | 2012-12-05 | 2013-02-27 | 苏州大学 | 一种均匀稳定的纳米银水溶液的制备方法 |
| CN105664168A (zh) * | 2016-03-02 | 2016-06-15 | 中国科学院武汉植物园 | 一种载药纳米银粒子的制备方法及应用 |
| CN106075557A (zh) * | 2016-06-24 | 2016-11-09 | 青岛中腾生物技术有限公司 | 一种可形成含有纳米孔隙柔性膜的液体创口保护材料 |
| CN106924803A (zh) * | 2017-05-05 | 2017-07-07 | 江南大学 | 一种高性能医用液体创可贴及其制备方法 |
| CN108578762A (zh) * | 2018-05-21 | 2018-09-28 | 上海耐定工贸有限公司 | 一种方便快捷的液体创口贴及其制备方法 |
| CN108904876A (zh) * | 2018-10-15 | 2018-11-30 | 长春艾迪尔医用科技发展有限公司 | 一种液体创口敷料及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mirhaj et al. | An overview on the recent advances in the treatment of infected wounds: Antibacterial wound dressings | |
| US6093414A (en) | Silver-based antimicrobial compositions | |
| CA2263473C (en) | Silver-based antimicrobial compositions | |
| Forrest | Development of wound therapy from the Dark Ages to the present | |
| EP2881122B1 (en) | Di-quaternary ammonium salts made of organosilicone as antibacterial agents | |
| ES2576132T3 (es) | Composición que comprende nanopartículas de TiO2 | |
| WO2004045572A1 (en) | Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil | |
| CN109568634B (zh) | 一种还原氧化石墨烯抗菌敷料及其制备方法 | |
| IT201900002767A1 (it) | Presidio medico per la cura di patologie cutanee e relativo metodo di realizzazione | |
| DE60031016T2 (de) | Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen | |
| Cui et al. | A carrier-free, injectable, and self-assembling hydrogel based on carvacrol and glycyrrhizin exhibits high antibacterial activity and enhances healing of MRSA-infected wounds | |
| CN110859989B (zh) | 一种液体创可贴及其制备方法 | |
| CN105169464B (zh) | 一种天然蜂蜜伤口敷料及其制备方法与应用 | |
| JPH07148280A (ja) | マスク | |
| CN105012581A (zh) | 一种芦荟舒爽抑菌组合物、应用及其制备方法 | |
| CN110947028A (zh) | 一种黄豆浸取液制备的Ag纳米粒子及其液体创口贴制备方法 | |
| CN114452435B (zh) | 一种能够快速生效的高亲和液体敷料 | |
| CN106474137B (zh) | 一种含有叶绿素的口腔溃疡贴膜及其制备方法 | |
| EP3656404A1 (en) | Film for topical use for treating skin lesions and method for producing and applying same | |
| KR102445058B1 (ko) | 사용성 및 위생성이 향상된 롤 타입 연고 | |
| WO2010127647A1 (de) | Zusammensetzungen für wundbehandlungen im human-, und veterinärbereich | |
| KR101919499B1 (ko) | 프로폴리스와 알파피넨을 유효성분으로 함유하는 병원성 슈퍼박테리아에 대한 항균 조성물 | |
| CN106236835A (zh) | 一种植物精油喷剂及其制备方法和应用 | |
| CN115177782B (zh) | 一种高透气、促愈合的液体创可贴及其制备方法 | |
| RU2231368C1 (ru) | Ранозаживляющее покрытие с прополисом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200403 |
|
| RJ01 | Rejection of invention patent application after publication |